Cargando…

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection

Detalles Bibliográficos
Autores principales:	Marinos, Alejandro, Ramdial, Jeremy L, Saliba, Rima M., Khawaja, Fareed, Alousi, Amin M., Rondon, Gabriela, Chen, Julianne, Ledesma, Celina, Chemaly, Dr. Roy F., Champlin, Richard E., Marin, David, Daher, May, Rezvani, Katayoun, Shpall, Elizabeth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2023
Materias:	Poster Session: Infectious Diseases and Cytotoxic T Lymphocytes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899537/ http://dx.doi.org/10.1016/S2666-6367(23)00518-3

Ejemplares similares

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Transplant Providers’ Perceptions of COVID-19 Vaccination in the Wake of a Global Pandemic
por: Spallone, Amy, et al.
Publicado: (2022)

Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19
por: Vasileiou, Spyridoula, et al.
Publicado: (2021)

Outcomes of COVID-19 Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients Treated with Hyperbaric Oxygen: A Case Series
por: Usman, Shireen, et al.
Publicado: (2022)

Evusheld™ Pre-Exposure COVID-19 Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant (HSCT) and Cellular Therapy Recipients: A Single Institution Retrospective Series
por: DePriest, Brittany Paige, et al.
Publicado: (2023)

Stool Screening for Sars-Cov-2 RNA for COVID-19 in Patients Undergoing Hematopoietic Cell Transplantation, Cellular Therapy, and Induction Chemotherapy
por: Severyn, Christopher J., et al.
Publicado: (2023)

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
por: Ionescu, Filip, et al.
Publicado: (2023)

Clinical Presentation and Outcomes of COVID-19 Following Hematopoietic Cell Transplantation
por: Camargo, Jose F., et al.
Publicado: (2021)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

A Portrait of Sars-Cov-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature
por: Bailey, Adrian, et al.
Publicado: (2022)

Humoral Immunogenicity of Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study
por: Riches, Marcie L., et al.
Publicado: (2022)

Efficacy of Sars-Cov-2 Vaccine in Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy Patients; A Single Study Experience
por: Zhuang, Eric, et al.
Publicado: (2022)

Vaccination Against Sars-Cov-2 Induces Robust Humoral Immune Response in Patients with Previous Hematologic Stem Cell Transplantation
por: Roldan, Elisa, et al.
Publicado: (2022)

Favorable Outcomes of Pediatric Hematopoietic Cell Transplant Patients Receiving Regen-COV2 for Prophylaxis Against Severe COVID-19 Disease
por: Graham, Rudi-Ann Tamara, et al.
Publicado: (2022)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Humoral Response to COVID-19 Vaccination Given Pre-Cellular Therapy Wanes in Patients after Cellular Therapy: An Argument for Full Reimmunization
por: Shah, Gunjan L., et al.
Publicado: (2022)

Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System
por: Chu, Yaya, et al.
Publicado: (2023)

Efficacy of Tixagevimab-Cilgavimab in Preventing Sars-Cov-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients
por: McGann, Mary, et al.
Publicado: (2023)

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

Immunogenicity and Safety of a Heterologous COVID-19 Vaccine Regimen in Hematopoietic Stem Cell Transplant Recipients
por: Fatobene, Giancarlo, et al.
Publicado: (2023)

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2023)

COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
por: Moreb, Jan S., et al.
Publicado: (2023)

Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience
por: Srinivasan, Krithika, et al.
Publicado: (2022)

2119. Predictive Value of the Immunodeficiency Scoring Index for COVID-19 Related Outcomes in Hematopoietic Transplant Recipients
por: Daher, Marilyne, et al.
Publicado: (2022)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation
por: Saliba, Rima M., et al.
Publicado: (2020)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies
por: Saliba, Rima M., et al.
Publicado: (2022)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
por: Khawaja, Fareed, et al.
Publicado: (2022)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation
por: Cao, Kai, et al.
Publicado: (2018)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rc1i7qlh32cu98hqnmsmcrcf2n